en · de · es · pt
bench-notes.peptides6579.com › Blog › Bremelanotide Background And Receptor Pharmacology — What the Evidence Shows

Bremelanotide Background And Receptor Pharmacology — What the Evidence Shows

By Editorial Desk · published 2026-06-17 · last reviewed 2026-07-11 · Blog

The short version of MC4R fits in a sentence. The long version — which is the one that helps — is below.

This page was last updated on 2026-07-11 and is reviewed periodically as new material appears.

Bremelanotide Background and Receptor Pharmacology

Receptor activation in hypothalamic and limbic circuits is the mechanism most often cited for the observed effects on sexual desire. Signalling through MC4R couples to Gs proteins and raises intracellular cyclic AMP, which in turn modulates dopaminergic tone in reward-related pathways. Because the peptide reaches the central nervous system after subcutaneous administration, peripheral vascular changes are regarded as secondary rather than primary. The precise neural circuits that translate receptor occupancy into behavioural change remain incompletely mapped, and published accounts describe the pathway in general terms rather than as a fully resolved sequence.

Development began with intranasal formulations investigated for erectile dysfunction, but blood pressure elevation limited that route and prompted a switch to subcutaneous delivery. Clinical testing then shifted toward hypoactive sexual desire disorder in premenopausal women, and a subcutaneous product received United States approval in 2019. Later trials examined other populations with mixed results, and questions about effect size, durability and patient selection remain open in the peer-reviewed literature. Research interest continues in parallel with the broader melanocortin field, where several synthetic analogues are studied together.

Melanocortin Receptor Agonist Pharmacology

Clinical development of bremelanotide proceeded through several reformulation attempts. An early intranasal version was discontinued, and a subcutaneous auto-injector formulation later received approval for hypoactive sexual desire disorder in premenopausal women. Approval decisions have varied by country and over time, and the product has not been universally adopted. Blood pressure elevation is a documented effect, which is why some jurisdictions require monitoring after administration. The clinical evidence base continues to evolve as additional studies are published.

Bremelanotide is a cyclic heptapeptide that acts as an agonist at melanocortin receptors. It binds MC1R, MC3R, MC4R, and MC5R, with MC4R activation considered most relevant to sexual desire pathways in the central nervous system. The molecule is a synthetic analog of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation and energy regulation. Early research explored its use in tanning before attention shifted toward sexual dysfunction applications. Receptor binding affinity varies across these subtypes.

Activation of MC4R in the hypothalamus is thought to influence dopaminergic signaling, which in turn affects arousal and desire. This mechanism differs from that of phosphodiesterase type 5 inhibitors, which act primarily on vascular smooth muscle in the genital region. Because the pathway is central rather than peripheral, effects are not strictly dependent on local blood flow. The precise downstream cascade linking receptor binding to behavioral outcomes remains an area of ongoing investigation.

Pt-141 at a glance

PropertyValueNotes
Research codePT-141Used in early literature before the generic name became common
Generic nameBremelanotideInternational nonproprietary name
Peptide classCyclic heptapeptideSeven residues joined by a lactam bridge
Primary receptorMC4RLower affinity reported at MC1R, MC3R and MC5R
Route studied clinicallySubcutaneous injectionIntranasal route was abandoned after pressor effects

Receptor Mechanism And Pharmacokinetics

After subcutaneous dosing, peak plasma concentrations appear within roughly one hour, and elimination is fast, with a half-life on the order of a few hours. Degradation is mainly proteolytic, and at least one circulating fragment retains receptor activity, so parent-drug levels alone do not describe total exposure. Clearance does not depend heavily on hepatic cytochrome enzymes, which lowers the likelihood of common metabolic interaction routes. Data in renal or hepatic impairment are limited. Repeated dosing does not appear to produce marked accumulation given the short half-life.

Reported pharmacodynamic effects include transient rises in blood pressure and heart rate, flushing, nausea and headache, appearing soon after dosing and resolving within hours. These responses were dose-related in early studies and shaped the label's cardiovascular cautions and blood pressure monitoring advice. Gastrointestinal upset is the most frequent reason cited for discontinuation in trials. Whether the vascular signal attenuates with repeated use is not settled. Central effects on desire are described as emerging over weeks rather than immediately, which points to a cumulative rather than acute process.

Related pages on this site

Receptor Pharmacology And Mechanism

Melanocortin receptors form a family of five G-protein-coupled proteins, labelled MC1R through MC5R, that respond to peptides derived from pro-opiomelanocortin. Alpha-melanocyte-stimulating hormone and adrenocorticotropic hormone are the best-known endogenous ligands. The receptors are distributed differently across tissues, so a single agonist can produce effects in the brain, skin, adrenal gland and vasculature. This distribution explains why one peptide can influence both pigmentation and motivated behaviour.

Bremelanotide is a cyclic heptapeptide that binds several melanocortin receptors rather than one. In vitro assays report agonist activity at MC1R, MC3R, MC4R and MC5R, with MC4R generally treated as the subtype most relevant to sexual effects. MC4R is expressed in hypothalamic nuclei involved in appetite, energy balance and motivated behaviour, which provides a plausible route for central action. Selective MC4R agonists studied in animals produce comparable behavioural changes, supporting that interpretation.

Supporting material

== Economics == The neon tetra was first imported from South America and was described by renowned ichthyologist George S. Myers in 1936, and named after William T. Innes. P. innesi is one of the most popular aquarium fish, with about 2 million sold in the US each month. Most neon tetras available in the United States are imported from Southeast Asia, where they are farm-raised, or to a lesser extent from Colombia, Peru, and Brazil, where they are collected from the wild. With the exception of home aquarists and a few commercial farms that breed neon tetras experimentally, captive breeding on a commercial scale is nonexistent in the USA.

== Controversy == Scientists associated with the initial development of recombinant DNA methods recognized that the potential existed for organisms containing recombinant DNA to have undesirable or dangerous properties. At the 1975 Asilomar Conference on Recombinant DNA, these concerns were discussed and a voluntary moratorium on recombinant DNA research was initiated for experiments that were considered particularly risky. This moratorium was widely observed until the US National Institutes of Health developed and issued formal guidelines for rDNA work. Today, recombinant DNA molecules and recombinant proteins are usually not regarded as dangerous. However, concerns remain about some organisms that express recombinant DNA, particularly when they leave the laboratory and are introduced into the environment or food chain. These concerns are discussed in the articles on genetically modified organisms and genetically modified food controversies. Furthermore, there are concerns about the by-products in biopharmaceutical production, where recombinant DNA result in specific protein products. The major by-product, termed host cell protein, comes from the host expression system and poses a threat to the patient's health and the overall environment.

Nearly two billion people in the developing world are deficient in zinc. Groups at risk include children in developing countries and elderly with chronic illnesses. In children, it causes an increase in infection and diarrhea and contributes to the death of about 800,000 children worldwide per year. The World Health Organization advocates zinc supplementation for severe malnutrition and diarrhea. Zinc supplements help prevent disease and reduce mortality, especially among children with low birth weight or stunted growth. However, zinc supplements should not be administered alone, because many in the developing world have several deficiencies, and zinc interacts with other micronutrients. While zinc deficiency is usually due to insufficient dietary intake, it can be associated with malabsorption, acrodermatitis enteropathica, chronic liver disease, chronic renal disease, sickle cell disease, diabetes, malignancy, and other chronic illnesses. In the United States, a federal survey of food consumption determined that for women and men over the age of 19, average consumption was 9.7 and 14.2 mg/day, respectively. For women, 17% consumed less than the EAR, for men 11%. The percentages below EAR increased with age. The most recent published update of the survey (NHANES 2013–2014) reported lower averages – 9.3 and 13.2 mg/day – again with intake decreasing with age. Symptoms of mild zinc deficiency are diverse.

In South America, Colombia has been in the midst of a civil war which has been waged since 1964 between the Colombian government and aligned right-wing paramilitaries against two Marxist–Leninist guerrilla groups, namely the National Liberation Army and Revolutionary Armed Forces of Colombia. In Peru, there has been an internal conflict between the Peruvian government and Marxist–Leninist–Maoist militants including the Shining Path. The 2021 Peruvian general election was won by presidential candidate Pedro Castillo on the Marxist–Leninist program put forward by Free Peru. The early 21st century also saw the election of socialist governments in several Latin American nations, in what has come to be known as the "pink tide"; dominated by the Venezuelan government of Hugo Chávez; this trend also saw the election of Evo Morales in Bolivia, Rafael Correa in Ecuador, and Daniel Ortega in Nicaragua. Forging political and economic alliances through international organisations like the Bolivarian Alliance for the Americas, these socialist governments allied themselves with Marxist–Leninist Cuba. Although none espoused a Stalinist path directly, most admitted to being significantly influenced by Marxist theory. Venezuelan president Hugo Chávez declared himself a Trotskyist during the swearing-in of his cabinet two days before his inauguration on 10 January 2007.

== External links == Kyle Hardingham's playing statistics from AFL Tables Kyle Hardingham at AustralianFootball.com Kyle Hardingham's WAFL playing statistics at WAFLFootyFacts.net Draft Profile on afl.com.au

Sources: en.wikipedia.org

Notes from published material

As an ointment, tacrolimus is used in the treatment of dermatitis (eczema), in particular atopic dermatitis, if topical corticosteroids and moisturisers fail in helping. It suppresses inflammation in a similar way to steroids, and is equally as effective as a mid-potency steroid. An important advantage of tacrolimus is that, unlike steroids, it does not cause skin thinning (atrophy), or other steroid related side effects. It is applied on the active lesions until they heal off, but may also be used continuously in low doses (twice a week), and applied to the thinner skin over the face and eyelids. Clinical trials of up to one year have been conducted. Recently it has also been used to treat segmental vitiligo in children, especially in areas on the face.

=== 1987 === January 16: Natives within the Party who oppose his policies of economic redevelopment (Perestroika). It is Gorbachev's hope that through initiatives of openness, debate and participation, that the Soviet people will support Perestroika. February 25: Phosphorite War breaks out in Estonia. April 15: An insurrection occurred in Sri Lanka by the Marxist–Leninist group, JVP. June 12: During a visit to West Berlin, U.S. President Ronald Reagan challenges Soviet General Secretary Mikhail Gorbachev in a speech: "Mr. Gorbachev, tear down this wall!" (The Berlin Wall). June 15: Famous Italian Singer and Songwriter Adriano Celentano lands in Moscow to present his movie Joan Lui in Soviet theaters, another step that opens the Soviet world to the Western one. September 10: The Battle of Cuito Cuanavale, Angola begins and further intensifies the South African Border War. September 30: Mohammad Najibullah becomes President of Afghanistan and implements a policy of National Reconciliation as a means of putting an end to the Soviet–Afghan War as well as beginning an end to Soviet influence in the country. December: A short war was fought between Thailand and Laos. December 8: The Intermediate-Range Nuclear Forces Treaty is signed in Washington, D.C. by U.S. President Ronald Reagan and Soviet leader Mikhail Gorbachev. Some later claim this was the unofficial beginning of the end of the Cold War. Gorbachev agrees to START I treaty. December 9: The First Intifada was waged by Palestinians against the Israeli government.

Dyson suggested that philosophers can be broadly if simplistically, divided into lumpers and splitters. These roughly correspond to Platonists, who regard the world as made up of ideas, and materialists, who imagine it divided into atoms.

=== 3D devices for glucose detection === Whitesides' group also developed a 3D paper-based microfluidic device for glucose detection that can produce calibration curves on-chip because of the improved fluid flow design. This 3D device consists of layers of paper patterned with microfluidic channels that are connected by layers of double-sided adhesive tape with holes. The holes in the tape permit flow between channels in alternating layers of paper, so this device allows for more complicated flow paths and enables the detection of multiple samples in a large number (up to ~1,000) of detection zones in the last layer of paper. More recently, 3D paper-based microfluidic devices assembled using origami were developed. Unlike Whitesides' design, these devices utilize a single layer of patterned paper that is then folded into multiple layers before sample solution is injected into the device. Subsequently, the device can be unfolded, and each layer of the device can be analyzed for the simultaneous detection of multiple analytes. This device is simpler and less expensive to fabricate than the aforementioned device using multiple layers of paper. Mixing between the channels in the different layers was not an issue in either device, so both devices were successful in quantifying glucose and BSA in multiple samples simultaneously.

Sources: en.wikipedia.org

Frequently asked questions

What does the PT-141 code refer to?

The code designates bremelanotide, a cyclic heptapeptide melanocortin receptor agonist. It served as an internal research identifier before the compound entered formal clinical development. The code and the generic name refer to the same molecule.

Which receptor is considered the principal target?

MC4R is generally described as the principal target, based on binding affinity and functional assays. Activity at MC1R, MC3R and MC5R is reported as weaker. Receptor selectivity is one reason the compound was pursued for central rather than vascular effects.

How does it relate to melanotan II?

Both are synthetic melanocortin analogues built on a similar cyclic peptide scaffold. Bremelanotide is described in the literature as a metabolite-derived analogue of melanotan II rather than the same substance. The two differ in terminal modifications, which affect half-life and receptor profile.

What is PT-141?

PT-141 is the research code for bremelanotide, a cyclic peptide developed as a melanocortin receptor agonist. The code has appeared in literature and catalog listings since early development. Bremelanotide is the international nonproprietary name.

Network